TDP-43-mediated alternative polyadenylation is associated with a reduction in VPS35 and VPS29 expression in frontotemporal dementia
Metrics
Details
- Title
- TDP-43-mediated alternative polyadenylation is associated with a reduction in VPS35 and VPS29 expression in frontotemporal dementia
- Creators
- V. Maheswari JawaharY. Zeng - Stanford UniversityE.M. Armour - Mayo Clinic in FloridaM. Yue - Mayo Clinic in FloridaK. Citrano - Mayo Clinic in FloridaA. Lovchykova - Stanford UniversityM.M. ReevesB. Rawlinson - Mayo Clinic in FloridaM. DeTure - Mayo Clinic in FloridaJ.A. Dunmore - Mayo Clinic in FloridaY. Song - Mayo Clinic in FloridaS.K. Ball - Mayo Clinic in FloridaZ.K. Wszolek - Mayo Clinic in FloridaN.R. Graff-Radford - Mayo Clinic in FloridaB.F. Boeve - Mayo ClinicD.S. Knopman - Mayo ClinicG.S. Day - Mayo Clinic in FloridaS.A. Small - Columbia UniversityD.W. DicksonM.E. Ward - National Institute of Neurological Disorders and StrokeT.F. Gendron - Mayo Clinic in FloridaY. Zhang - Mayo Clinic in FloridaM. Prudencio - Mayo Clinic in FloridaA.D. Gitler - Stanford UniversityL. Petrucelli - Mayo Clinic in Florida
- Publication Details
- PLoS biology, Vol.24(1), e3003573
- Publisher
- PUBLIC LIBRARY SCIENCE; SAN FRANCISCO
- Number of pages
- 19
- Grant note
- Mayo Foundation for Medical Education and ResearchTarget ALSThe Phil and Penny Knight Initiative for Brain ResilienceLarry L. Hillblom FoundationBrightFocus FoundationNational Institutes of Health: U54NS123743 Alzheimer's AssociationRobert Packard Center for ALS Research, Johns Hopkins University
This work was supported by a postdoctoral scholar award from The Phil and Penny Knight Initiative for Brain Resilience at the Wu Tsai Neurosciences Institute, Stanford University (Y.Z.; https://brainresilience.stanford.edu/about-knight-initiative), and by a fellowship grant from the Larry L. Hillblom foundation (Y.Z.; https://llhf.org/). This work was also funded by the Mayo Foundation for Medical Education and Research (L.P.; https://www.mayoclinic.org/), the Alzheimer's Association (L.P., A.D.G., S.S., M.W.; https://www.alz.org/), the Target ALS Foundation (M.P., Y.-J.Z., A.D.G., L.P.; https://www.targetals.org/), the Robert Packard Center for ALS Research at Johns Hopkins University (L.P.; https://packardcenter.org/), the BrightFocus Foundation (M.P.; https://www.brightfocus.org/), and the National Institutes of Health [U54NS123743 (M.P., A.D.G., L.P.), R01NS120992 (M.P.), P01NS084974 (D.W.D., T.F.G., Y.-J.Z., L.P.), R01NS117461 (T.F.G., Y.-J.Z.), R35NS137159 (A.D.G.), R01AG064690 (A.D.G.), R35NS097273 (L.P.); (https://www.nih.gov/)]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
- Comment
- Export Date: 27 February 2026; Cited By: 0
- Academic Unit
- Level 02 - Executives; Executives; UMMG Department of Neurology
- Resource Type
- Journal article
- PMID
- 41490046
- Record Identifier
- 991032995730602976